The association of NLRP3 and TNFRSF1A polymorphisms with risk of ankylosing spondylitis and treatment efficacy of etanercept

Background To discover how NLRP 3 and TNFRSF 1A polymorphisms affect the efficacy of traditional medicine and etanercept for ankylosing spondylitis ( AS ) patients. Methods Single nucleotide polymorphism ( SNP ) and haplotype analyses were conducted based on determined NLRP 3 and TNFRSF 1A among AS patients. We subsequently analyzed the relationship between relevant clinical indexes and polymorphisms of NLRP 3 and TNFRSF 1A . Results The 4 SNP loci on NLRP 3 and 3 SNP loci on TNFRSF 1A showed significant linkage disequilibrium, respectively. The T allele of NLRP 3 rs4612666 and the T allele of TFRSF 1A rs4149570 are both associated with AS ( P <.05). The T‐A‐C‐T haplotype of NLRP 3 as well as the G‐C‐C, T‐C‐C, T‐C‐T, and T‐T‐T haplotypes of TFRSF 1A are associated with AS ( P <.05). The morning stiffness time, BASDAI scoring, and ESR of patients receiving etanercept were significantly higher than those receiving traditional medicine. T allele of NLRP 3 rs4612666 had a significantly greater negative impact on the ASAS 20 improvement than C allele. Whereas the A allele of NLRP 3 rs3806268 had a significantly greater positive impact on the ASAS 20 improvement than G allele. There is no significant association between SNP and efficacy of traditional medicine in the treatment of AS . Conclusion NLRP 3 and TFRSF 1A (rs4149570) are associated with AS susceptibility. There is a significant association between NLRP 3 polymorphisms and treatment of etanercept.